Artelo Biosciences, a clinical-stage biopharmaceutical company based in Solana Beach, California, focuses on developing therapeutics targeting lipid-signaling pathways and the endocannabinoid system. Its key programs include ART27.13 for anorexia and ART26.12 for cancer, pain, and anxiety.
Artelo Biosciences (ARTL) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Artelo Biosciences's actual EPS was -$4.32, missing the estimate of -$0.80 per share, resulting in a -442.99% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
